Anti-GM1/GD1a complex antibodies in GBS sera specifically recognize the hybrid dimer GM1-GD1a

Laura Mauri, Riccardo Casellato, Maria G. Ciampa, Yoshinori Uekusa, Koichi Kato, Ken Ichi Kaida, Mayumi Motoyama, Susumu Kusunoki, Sandro Sonnino

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

It is now emerging the new concept that the antibodies from some patients with Guillain-Barré syndrome (GBS) recognize an antigenic epitope formed by two different gangliosides, a ganglioside complex (GSC). We prepared the dimeric GM1-GD1a hybrid ganglioside derivative that contains two structurally different oligosaccharide chains to mimic the GSC. We use this compound to analyze sera from GBS patients by high-performance thin-layer chromatography immunostaining and enzyme-linked immunosorbent assay. We also synthesized the dimeric GM1-GM1 and GD1a-GD1a compounds that were used in control experiments together with natural gangliosides. The hybrid dimeric GM1-GD1a was specifically recognized by human sera from GBS patients that developed anti-oligosaccharide antibodies specific for grouped complex oligosaccharides, confirming the information that GBS patients developed antibodies against a GSC. High-resolution 1H- 13C heteronuclear single-quantum coherence-nuclear overhauser effect spectroscopy nuclear magnetic resonance experiments showed an interaction between the IV Gal-H1 of GM1 and the IV Gal-H2 of GD1a suggesting that the two oligosaccharide chains of the dimeric ganglioside form a single epitope recognized by a single-antibody domain. The availability of a method capable to prepare several hybrid gangliosides, and the availability of simple analytical approaches, opens new perspectives for the understanding and the therapy of several neuropathies.

Original languageEnglish
Pages (from-to)352-360
Number of pages9
JournalGlycobiology
Volume22
Issue number3
DOIs
Publication statusPublished - 2012 Mar
Externally publishedYes

Fingerprint

Gangliosides
Dimers
Antibodies
Oligosaccharides
Serum
Epitopes
Single-Domain Antibodies
Availability
Thin layer chromatography
Immunosorbents
Thin Layer Chromatography
Anti-Idiotypic Antibodies
Nuclear magnetic resonance spectroscopy
Magnetic Resonance Spectroscopy
Enzyme-Linked Immunosorbent Assay
Assays
Experiments
Derivatives
Enzymes

Keywords

  • antibodies
  • ganglioside complexes
  • GBS
  • lipid rafts
  • neuropathies

ASJC Scopus subject areas

  • Biochemistry

Cite this

Mauri, L., Casellato, R., Ciampa, M. G., Uekusa, Y., Kato, K., Kaida, K. I., ... Sonnino, S. (2012). Anti-GM1/GD1a complex antibodies in GBS sera specifically recognize the hybrid dimer GM1-GD1a. Glycobiology, 22(3), 352-360. https://doi.org/10.1093/glycob/cwr139

Anti-GM1/GD1a complex antibodies in GBS sera specifically recognize the hybrid dimer GM1-GD1a. / Mauri, Laura; Casellato, Riccardo; Ciampa, Maria G.; Uekusa, Yoshinori; Kato, Koichi; Kaida, Ken Ichi; Motoyama, Mayumi; Kusunoki, Susumu; Sonnino, Sandro.

In: Glycobiology, Vol. 22, No. 3, 03.2012, p. 352-360.

Research output: Contribution to journalArticle

Mauri, L, Casellato, R, Ciampa, MG, Uekusa, Y, Kato, K, Kaida, KI, Motoyama, M, Kusunoki, S & Sonnino, S 2012, 'Anti-GM1/GD1a complex antibodies in GBS sera specifically recognize the hybrid dimer GM1-GD1a', Glycobiology, vol. 22, no. 3, pp. 352-360. https://doi.org/10.1093/glycob/cwr139
Mauri, Laura ; Casellato, Riccardo ; Ciampa, Maria G. ; Uekusa, Yoshinori ; Kato, Koichi ; Kaida, Ken Ichi ; Motoyama, Mayumi ; Kusunoki, Susumu ; Sonnino, Sandro. / Anti-GM1/GD1a complex antibodies in GBS sera specifically recognize the hybrid dimer GM1-GD1a. In: Glycobiology. 2012 ; Vol. 22, No. 3. pp. 352-360.
@article{274dbeceebbd419fbefadd781b43c071,
title = "Anti-GM1/GD1a complex antibodies in GBS sera specifically recognize the hybrid dimer GM1-GD1a",
abstract = "It is now emerging the new concept that the antibodies from some patients with Guillain-Barr{\'e} syndrome (GBS) recognize an antigenic epitope formed by two different gangliosides, a ganglioside complex (GSC). We prepared the dimeric GM1-GD1a hybrid ganglioside derivative that contains two structurally different oligosaccharide chains to mimic the GSC. We use this compound to analyze sera from GBS patients by high-performance thin-layer chromatography immunostaining and enzyme-linked immunosorbent assay. We also synthesized the dimeric GM1-GM1 and GD1a-GD1a compounds that were used in control experiments together with natural gangliosides. The hybrid dimeric GM1-GD1a was specifically recognized by human sera from GBS patients that developed anti-oligosaccharide antibodies specific for grouped complex oligosaccharides, confirming the information that GBS patients developed antibodies against a GSC. High-resolution 1H- 13C heteronuclear single-quantum coherence-nuclear overhauser effect spectroscopy nuclear magnetic resonance experiments showed an interaction between the IV Gal-H1 of GM1 and the IV Gal-H2 of GD1a suggesting that the two oligosaccharide chains of the dimeric ganglioside form a single epitope recognized by a single-antibody domain. The availability of a method capable to prepare several hybrid gangliosides, and the availability of simple analytical approaches, opens new perspectives for the understanding and the therapy of several neuropathies.",
keywords = "antibodies, ganglioside complexes, GBS, lipid rafts, neuropathies",
author = "Laura Mauri and Riccardo Casellato and Ciampa, {Maria G.} and Yoshinori Uekusa and Koichi Kato and Kaida, {Ken Ichi} and Mayumi Motoyama and Susumu Kusunoki and Sandro Sonnino",
year = "2012",
month = "3",
doi = "10.1093/glycob/cwr139",
language = "English",
volume = "22",
pages = "352--360",
journal = "Glycobiology",
issn = "0959-6658",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Anti-GM1/GD1a complex antibodies in GBS sera specifically recognize the hybrid dimer GM1-GD1a

AU - Mauri, Laura

AU - Casellato, Riccardo

AU - Ciampa, Maria G.

AU - Uekusa, Yoshinori

AU - Kato, Koichi

AU - Kaida, Ken Ichi

AU - Motoyama, Mayumi

AU - Kusunoki, Susumu

AU - Sonnino, Sandro

PY - 2012/3

Y1 - 2012/3

N2 - It is now emerging the new concept that the antibodies from some patients with Guillain-Barré syndrome (GBS) recognize an antigenic epitope formed by two different gangliosides, a ganglioside complex (GSC). We prepared the dimeric GM1-GD1a hybrid ganglioside derivative that contains two structurally different oligosaccharide chains to mimic the GSC. We use this compound to analyze sera from GBS patients by high-performance thin-layer chromatography immunostaining and enzyme-linked immunosorbent assay. We also synthesized the dimeric GM1-GM1 and GD1a-GD1a compounds that were used in control experiments together with natural gangliosides. The hybrid dimeric GM1-GD1a was specifically recognized by human sera from GBS patients that developed anti-oligosaccharide antibodies specific for grouped complex oligosaccharides, confirming the information that GBS patients developed antibodies against a GSC. High-resolution 1H- 13C heteronuclear single-quantum coherence-nuclear overhauser effect spectroscopy nuclear magnetic resonance experiments showed an interaction between the IV Gal-H1 of GM1 and the IV Gal-H2 of GD1a suggesting that the two oligosaccharide chains of the dimeric ganglioside form a single epitope recognized by a single-antibody domain. The availability of a method capable to prepare several hybrid gangliosides, and the availability of simple analytical approaches, opens new perspectives for the understanding and the therapy of several neuropathies.

AB - It is now emerging the new concept that the antibodies from some patients with Guillain-Barré syndrome (GBS) recognize an antigenic epitope formed by two different gangliosides, a ganglioside complex (GSC). We prepared the dimeric GM1-GD1a hybrid ganglioside derivative that contains two structurally different oligosaccharide chains to mimic the GSC. We use this compound to analyze sera from GBS patients by high-performance thin-layer chromatography immunostaining and enzyme-linked immunosorbent assay. We also synthesized the dimeric GM1-GM1 and GD1a-GD1a compounds that were used in control experiments together with natural gangliosides. The hybrid dimeric GM1-GD1a was specifically recognized by human sera from GBS patients that developed anti-oligosaccharide antibodies specific for grouped complex oligosaccharides, confirming the information that GBS patients developed antibodies against a GSC. High-resolution 1H- 13C heteronuclear single-quantum coherence-nuclear overhauser effect spectroscopy nuclear magnetic resonance experiments showed an interaction between the IV Gal-H1 of GM1 and the IV Gal-H2 of GD1a suggesting that the two oligosaccharide chains of the dimeric ganglioside form a single epitope recognized by a single-antibody domain. The availability of a method capable to prepare several hybrid gangliosides, and the availability of simple analytical approaches, opens new perspectives for the understanding and the therapy of several neuropathies.

KW - antibodies

KW - ganglioside complexes

KW - GBS

KW - lipid rafts

KW - neuropathies

UR - http://www.scopus.com/inward/record.url?scp=84856259019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856259019&partnerID=8YFLogxK

U2 - 10.1093/glycob/cwr139

DO - 10.1093/glycob/cwr139

M3 - Article

C2 - 21921061

AN - SCOPUS:84856259019

VL - 22

SP - 352

EP - 360

JO - Glycobiology

JF - Glycobiology

SN - 0959-6658

IS - 3

ER -